At the forefront of research, development, commercialization of innovative, and potential     best-in-class total solutions for valvular heart diseases



MicroPort CardioFlow launches VitaFlow Liberty™ at China Structural Week

MicroPort CardioFlow recently hosted a launch event for VitaFlow Liberty™, a next-generation product for TAVI. The product, presented at China Structural Week 2021 and the 5th China International Structural Heart Disease Conference held in Beijing, Shanghai, Guangzhou, and Xi'an, drew the attention of experts in the field of structural heart disease and triggered discussions on the development of the TAVI procedure.


First Motorized Retrievable Transcatheter Aortic Valve (TAVI) System - VitaFlow Liberty™ received approval for marketing in China

On 30th August 2021, MicroPort CardioFlow, announced that its transcatheter aortic valve system – VitaFlow Liberty™ has received approval for marketing by China’s National Medical Products Administration. As the first motorized retrievable transcatheter aortic valve system approved for marketing, VitaFlow Liberty™ leads as the first motorized retrievable system in the TAVI market.


MicroPort CardioFlow Announces 2021 Interim Results

Shanghai, China — MicroPort CardioFlow, announced on August 29, 2021 the interim results of the company for the six months ended June 30, 2021. During the period, the company recorded revenue of RMB86.2 million, representing an increase of 121.8% as compared to the corresponding period of last year, with the gross profit margin increased significantly by 11 percentage points to 55.1%.


The announcement of annual results of MicroPort CardioFlow Medtech Corporation for the year 2020

MicroPort CardioFlow is pleased to announce the results of the Company and its subsidiaries for the year ended December 31st, 2020.


MicroPort CardioFlow goes public on SEHK

February 4, 2021, Shanghai, China— MicroPort CardioFlow, is successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited (SEHK). Founded in 2015, MicroPort CardioFlow specializes in providing total medical solutions for the treatment of the most common aortic and mitral valve diseases, including aortic stenosis and mitral regurgitation.


MicroPort CardioFlow Completes Raising New Round of Funds

MicroPort CardioFlow had completed raising a new round of funds on the basis of a pre-money valuation of US$1.1 billion. The introduction prominent strategic investors, who are CPE, Hillhouse Capital Management, Ltd., Lake Bleu Capital, Gamnat, China Reform Conson Soochow Overseas Fund I L.P., Gortune Artemis Limited, and 3H Health Investment Fund I, L.P., raised approximately US$130 million.